Joakim Dillner (Former)
81 – 90 of 236
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
Three novel papillomaviruses (HPV109, HPV112 and HPV114) and their presence in cutaneous and mucosal samples.
(
- Contribution to journal › Article
-
Mark
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
(
- Contribution to journal › Article
-
Mark
Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women.
(
- Contribution to journal › Article
-
Mark
The interface of population-based cancer registries and biobanks in etiological and clinical research - current and future perspectives.
(
- Contribution to journal › Article
- 2009
-
Mark
EUROCOURSE: towards optimisation of the use of cancer registries for scientific excellence in cancer research in Europe: an FP7 ERA-net project
2009) 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology In EJC Supplements 7(2). p.201-202(
- Contribution to journal › Published meeting abstract
-
Mark
Male Circumcision and Serologically Determined Human Papillomavirus Infection in a Birth Cohort
(
- Contribution to journal › Article
-
Mark
Penile cancer: epidemiology, pathogenesis and prevention
(
- Contribution to journal › Article
-
Mark
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16-26 Years
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older
(
- Contribution to journal › Article